MWMark Weiser

Mark Weiser

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mark Weiser has a total of 546 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    INTENSIFY—a randomized, controlled trial to investigate the effect of an early intensified pharmacological treatment for major psychiatric disorders after treatment failure in the current episode: a study protocol

    by Cynthia Okhuijsen-Pfeifer, Alessandro Serretti, Eduard Vieta, Lidia Ilzarbe, Chiara Fabbri, Oliver Howes, K. Oliver Schubert, Scott R. Clark, Dennis Liu, Alex Hofer, et al.

  • Open Access

    Multivariable prediction of functional outcome after first-episode psychosis: a crossover validation approach in EUFEST and PSYSCAN

    by Margot I. E. Slot, Maria F. Urquijo Castro, Inge Winter - van Rossum, Hendrika H. van Hell, Dominic Dwyer, Paola Dazzan, Arija Maat, Lieuwe De Haan, Benedicto Crespo-Facorro, Birte Y. Glenthøj, et al.

    Several multivariate prognostic models have been published to predict outcomes in patients with first episode psychosis (FEP), but it remains unclear whether those predictions generalize to independent populations. Using a subset of demographic and clinical baseline predictors, we aimed to develop and externally validate different models predicting functional outcome after a FEP in the context of a schizophrenia-spectrum disorder (FES), based on a previously published cross-validation and machine learning pipeline. A crossover validation approach was adopted in two large, international cohorts (EUFEST, n = 338, and the PSYSCAN FES cohort, n = 226). Scores on the Global Assessment of Functioning scale (GAF) at 12 month follow-up were dichotomized to differentiate between poor (GAF current < 65) and good outcome (GAF current ≥ 65). Pooled non-linear support vector machine (SVM) classifiers trained on the separate cohorts identified patients with a poor outcome with cross-validated balanced accuracies (BAC) of 65-66%, but BAC dropped substantially when the models were applied to patients from a different FES cohort (BAC = 50–56%). A leave-site-out analysis on the merged sample yielded better performance (BAC = 72%), highlighting the effect of combining data from different study designs to overcome calibration issues and improve model transportability. In conclusion, our results indicate that validation of prediction models in an independent sample is essential in assessing the true value of the model. Future external validation studies, as well as attempts to harmonize data collection across studies, are recommended.


  • Open Access

    A naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort

    by Margot I.E. Slot, Hendrika H. van Hell, Inge Winter-Van Rossum, Paola Dazzan, Arija Maat, Lieuwe de Haan, Benedicto Crespo-Facorro, Birte Glenthøj, Stephen M. Lawrie, Colm McDonald, et al.


  • Open Access

    Extreme deviations from the normative model reveal cortical heterogeneity and associations with negative symptom severity in first-episode psychosis from the OPTiMiSE and GAP studies

    by Amanda Worker, Pierre Berthert, Andrew J. Lawrence, Seyed Mostafa Kia, Celso Arango, Richard Dinga, Silvana Galderisi, Birte Glenthøj, René S. Kahn, Anoushka Leslie, et al.

    There is currently no quantifiable method to predict long-term clinical outcomes in patients presenting with a first episode of psychosis. A major barrier to developing useful markers for this is biological heterogeneity, where many different pathological mechanisms may underly the same set of symptoms in different individuals. Normative modelling has been used to quantify this heterogeneity in established psychotic disorders by identifying regions of the cortex which are thinner than expected based on a normative healthy population range. These brain atypicalities are measured at the individual level and therefore potentially useful in a clinical setting. However, it is still unclear whether alterations in individual brain structure can be detected at the time of the first psychotic episode, and whether they are associated with subsequent clinical outcomes. We applied normative modelling of cortical thickness to a sample of first-episode psychosis patients, with the aim of quantifying heterogeneity and to use any pattern of cortical atypicality to predict symptoms and response to antipsychotic medication at timepoints from baseline up to 95 weeks (median follow-ups = 4). T1-weighted brain magnetic resonance images from the GAP and OPTiMiSE samples were processed with Freesurfer V6.0.0 yielding 148 cortical thickness features. An existing normative model of cortical thickness (n = 37,126) was adapted to integrate data from each clinical site and account for effects of gender and site. Our test sample consisted of control participants (n = 149, mean age = 26, SD = 6.7) and patient data (n = 295, mean age = 26, SD = 6.7), this sample was used for estimating deviations from the normative model and subsequent statistical analysis. For each individual, the 148 cortical thickness features were mapped to centiles of the normative distribution and converted to z-scores reflecting the distance from the population mean. Individual cortical thickness metrics of +/– 2.6 standard deviations from the mean were considered extreme deviations from the norm. We found that no more than 6.4% of psychosis patients had extreme deviations in a single brain region (regional overlap) demonstrating a high degree of heterogeneity. Mann-Whitney U tests were run on z-scores for each region and significantly lower z-scores were observed in FEP patients in the frontal, temporal, parietal and occipital lobes. Finally, linear mixed-effects modelling showed that negative deviations in cortical thickness in parietal and temporal regions at baseline are related to more severe negative symptoms over the medium-term. This study shows that even at the early stage of symptom onset normative modelling provides a framework to identify individualised cortical markers which can be used for early personalised intervention and stratification.


  • A randomized controlled trial of add-on naproxen, simvastatin and their combination for the treatment of schizophrenia or schizoaffective disorder

    by Mark Weiser, Linda Levi, Jinyoung Park, Igor Nastas, Valentin Matei, Michael Davidson, Ido Arad, Israel Dudkiewicz, John M. Davis


  • Cannabis Use and Symptomatic Relapse in First Episode Schizophrenia: Trigger or Consequence? Data From the OPTIMISE Study

    by Linda Levi, Mor Bar-Haim, Inge Winter-Van Rossum, Michael Davidson, Stefan Leucht, Wolfgang W Fleischhacker, Jinyoung Park, John M Davis, Renè S Kahn, Mark Weiser

    This analysis examined the relationship between cannabis use, compliance with antipsychotics and risk for relapse in patients in remission following a first episode of schizophrenia, schizophreniform, or schizoaffective disorder. Analyses were performed on data from a large European study on first episode of schizophrenia, schizophreniform, or schizoaffective disorder (OPTiMiSE). After 10 weeks of antipsychotic treatment, 282/446 patients (63%) met criteria for symptomatic remission; of whom 134/282 (47.5%) then completed a 1-year follow-up. Cross-lagged models and mediation models investigated the temporal relationships between cannabis use, compliance with antipsychotics, social functioning, and symptomatic worsening/relapse. Compared to nonusers, cannabis use increased risk for relapse, adjusted hazard ratio (HR) = 3.03 (SE = 0.32), P < .001, even in patients who were compliant with antipsychotic medication, adjusted HR = 2.89, (SE = 0.32), P < .001. Cannabis use preceded symptomatic worsening and was followed by worsening of Positive and Negative Syndrome Scale total score at the 1-year end-point (standardized β = 0.62, SE = 0.19, P = .001) and by worsening of social functioning (coef = −0.66, P ≤ .001). In patients in remission from their first episode of schizophrenia, schizophreniform, or schizoaffective disorder, cannabis use increases the rate of relapse in both compliant and noncompliant individuals. Importantly, the temporal relationship between cannabis and relapse was that cannabis use preceded later relapse, noncompliance, and decrease in social functioning, and not that patients began to relapse, then used cannabis. Further research with a precision psychiatry approach might identify those patients in particular danger of relapse when using cannabis.


  • Validation of the Collaborative Outcomes study on Health and Functioning during Infection Times (COH-FIT) questionnaire for adults

    by Marco Solmi, Trevor Thompson, Andrés Estradé, Agorastos Agorastos, Joaquim Radua, Samuele Cortese, Elena Dragioti, Friedrich Leisch, Davy Vancampfort, Lau Caspar Thygesen, et al.


  • Add-On Pramipexole for the Treatment of Schizophrenia and Schizoaffective Disorder

    by Linda Levi, Daisy Zamora, Igor Nastas, Ilan Gonen, Paull Radu, Valentin Matei, Adela M. Ciobanu, Anatol Nacu, Larisa Boronin, Lusian Karakrah, et al.

    Several small clinical trials have reported that the dopamine agonist pramipexole was beneficial in treating patients with schizophrenia. This 16-week, multicenter, double-blind, randomized, placebo-controlled study was conducted to test this hypothesis.


  • COVID-19 and severe mental illness in Israel: testing, infection, hospitalization, mortality and vaccination rates in a countrywide study

    by Nehama Goldberger, Tal Bergman-Levy, Ziona Haklai, Rinat Yoffe, Michael Davidson, Ehud Susser, Linda Levi, Tal Elhasid, Mark Weiser

    Previous studies on psychiatric patients infected with COVID-19 have reported a more severe course of disease and higher rates of mortality compared with the general population. This cohort study linked Israeli national databases including all individuals ever hospitalized for a psychiatric disorder (cases), and COVID-19 testing, infection, hospitalization, mortality, and vaccinations, between March 1st 2020 and March 31st 2021. Cases were 125,273 individuals aged 18 and above ever hospitalized in a psychiatric facility (ICD-10 F10-F69 or F90-F99), compared to the total population, n = 6,143,802. Compared with the total population, cases were less likely to be tested for COVID-19, 51.2% (95% CI: 50.8–51.7) vs 62.3% (95% CI 62.2–62.4) and had lower rates of confirmed COVID infection, 5.9% (95% CI: 5.8–6.1) vs 8.9% (95% CI: 8.9–8.9). Among those infected, risks for COVID-19 hospitalization, COVID-19 attributed mortality and all-cause mortality were higher for cases than the total population, adjusted odds ratios were 2.10; (95% CI: 1.96–2.25), 1.76; (95% CI: 1.54–2.01) and 2.02; (95% CI: 1.80–2.28), respectively. These risks were even higher for cases with non-affective psychotic disorders and bipolar disorder. Age adjusted rates of vaccination were lower in cases, 60.4% (95% CI: 59.9–60.8) vs 74.9% (95% CI: 74.8–75.0) in the total population, and particularly low for cases with non-affective psychotic disorders, 56.9% (95% CI: 56.3–57.6). This study highlights the need to increase testing for COVID-19 in individuals ever hospitalized for a psychiatric disorder, closely monitor those found positive, and to reach out to encourage vaccination.